The patient’s autoimmune hepatitis with cirrhosis (F4) and portal hypertension necessitates structured hepatology follow-up, including ALT, aspartate transaminase (AST), bilirubin, albumin, international normalized ratio (INR), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT; every 1–3 months initially, then every 3–6 months), and IgG levels to assess disease activity. This evidence concerns the gene GPT and portal hypertension.